Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals (NQ: IONS )

38.76 +0.37 (+0.96%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 Next >
Benzinga's Daily Brief On Trending Tickers For March 2, 2022: VanEck Russia ETF, AMC Entertainment, SoFi Technologies And More
Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022
Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,... 
Via Benzinga
What 5 Analyst Ratings Have To Say About Ionis Pharmaceuticals
Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Pfizer Backs Out Of Heart-Disease Deal, Leaving Ionis Stock To Crumble
Pfizer signed on to develop a high triglycerides treatment in November 2019. 
Via Investor's Business Daily
Why Are Ionis Pharmaceuticals Shares Tanking Today?
Pfizer Inc (NYSE: PFE) and Ionis Pharmaceuticals Inc (NASDAQ: IONS)  
Via Benzinga
Benzinga's Daily Brief On Trending Tickers For Feb. 25, 2022: GameStop, Tesla, AMD And More
Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news... 
Via Benzinga
Benzinga's Daily Brief On Trending Tickers For Feb. 23, 2022: Palantir, GameStop, Tesla, And More
Benzinga’s Daily Brief On Trending Tickers highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items... 
Via Benzinga
Benzinga's Daily Brief On Trending Tickers For Feb. 22, 2022: Tesla, GameStop, Lexicon And More
Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news... 
Via Benzinga
Where Ionis Pharmaceuticals Stands With Analysts
Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed ... 
Via Benzinga
Bear Market Bets In Biotech
Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020. 
Via Talk Markets
BofA Downgrades Ionis After Vupanorsen Setback: Are There Upcoming Catalysts That Can Help The Stock?
Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced on Monday the discontinuation of the Vupanorsen clinical development program. Following this, there are no high-impact catalysts for the next 12... 
Via Benzinga
Will Moderna Sidestep The Looming Sales Cliff After FDA Approves Covid Shot?
Currently, analysts expect Moderna sales to drop off after 2022. 
Via Investor's Business Daily
Benzinga Pro's Top 5 Stocks To Watch For Monday, Jan. 31, 2022: NFLX, BB, IONS, NXPI, EA
Today's 5 Stock Ideas: Netflix (NFLX) - Shares up premarket. Citigroup upgraded the stock from Neutral to Buy and announced a $450 price target. Also, Co-CEO Reed Hastings... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Madrigal Pharmaceuticals (NASDAQ:MDGL) shares rose 14.9% to $64.8 during Monday's pre-market session. The market value of their outstanding shares is at $1.1... 
Via Benzinga
Ionis' Eplontersen Receives FDA Orphan Drug Status For Misfolded Protein Disorder
The FDA has granted orphan drug designation to Ionis Pharmaceuticals Inc's (NASDAQ: IONS) eplontersen, an investigational antisense medicine for... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... 
Via Benzinga
Benzinga Asks: Which ARK Fund Would You Rather Buy And Hold For 5 Years?
One of the best-known and well-covered ETF companies over the past five years has been ARK Invest, led by Cathie Wood. With t... 
Via Benzinga
The Week Ahead In Biotech (Jan. 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week
Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. Here are the key catalysts that can sway biotech stocks in the unfolding week. 
Via Talk Markets
The Week Ahead In Biotech (Jan 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week
Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. On the regulatory front, the Food And Drug Administration... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2021
Upgrades According to Wells Fargo, the prior rating for Douglas Emmett Inc (NYSE: 
Via Benzinga
Jim Cramer Shares His Thoughts On Canadian Pacific Railway, Royalty Pharma And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Canadian Pacific Railway Limited (NYSE: 
Via Benzinga
The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive Phase 3 Data For Trofinetide In Rett Syndrome... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers ACADIA Pharmaceuticals (NASDAQ:ACAD) stock rose 18.35% to $22.96 during Tuesday's pre-market session. The company's market cap stands at $3.6 billion.... 
Via Benzinga
Ionis, AstraZeneca Ink Licensing Pact For Eplontersen In Protein Misfolding Disorder
Ionis Pharmaceuticals Inc (NASDAQ: IONS) has entered into a strategic collaboration agreement with AstraZeneca Plc (NASDAQ: AZN) to develop and... 
Via Benzinga
Pfizer Posts Vupanorsen Data From Mid-Stage Cardiovascular Disease Trial
Pfizer Inc (NYSE: PFE) has provided an update on the Phase 2b study of vupanorsen, investigational antisense therapy for cardiovascular (CV) risk reduction and severe... 
Via Benzinga
How Alnylam Pharmaceuticals Could Take On Pfizer With A 'Catalyst-Rich' 2022
Alnylam is working on a drug that could tackle transthyretin cardiomyopathy. 
Via Investor's Business Daily
Barron's Most Recent Picks And Pans: General Electric, Pfizer, Walt Disney And More
This weekend's Barron's cover story examines the revival of mall stocks. Other featured articles discuss why small-cap stocks are the next big thing and some energy... 
Via Benzinga
Ionis Pharmaceuticals, inc (IONS) Q3 2021 Earnings Call Transcript
IONS earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics... 
Via Benzinga
Topics Retirement
Exposures Pension
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.